Ashwani Verma
Stock Analyst at UBS
(4.32)
# 401
Out of 5,122 analysts
100
Total ratings
60.56%
Success rate
14.74%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CORT Corcept Therapeutics | Initiates: Neutral | $95 | $79.82 | +19.02% | 1 | Dec 16, 2025 | |
| LEGN Legend Biotech | Maintains: Buy | $54 → $48 | $21.92 | +118.98% | 4 | Dec 8, 2025 | |
| BHVN Biohaven | Downgrades: Neutral | $26 → $11 | $11.54 | -4.68% | 5 | Nov 26, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $163 → $188 | $170.50 | +10.26% | 7 | Nov 24, 2025 | |
| ALVO Alvotech | Maintains: Buy | $13 → $10 | $4.97 | +101.21% | 1 | Nov 18, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $195 → $220 | $230.84 | -4.70% | 1 | Nov 7, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $580 → $600 | $502.90 | +19.31% | 10 | Nov 6, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $35 → $40 | $45.37 | -11.84% | 5 | Nov 6, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Neutral | $20 | $21.55 | -7.19% | 4 | Oct 28, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $50 → $43 | $37.91 | +13.43% | 3 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $188 → $195 | $143.64 | +35.76% | 10 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $26 | $31.56 | -17.62% | 10 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $39 | $27.26 | +43.07% | 8 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $133 → $144 | $150.68 | -4.43% | 5 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $25.61 | -29.71% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $33 → $42 | $28.01 | +49.95% | 5 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $61 | $99.29 | -38.56% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $47 → $41 | $61.75 | -33.60% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.34 | -21.64% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $65.16 | +74.95% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $39.08 | -28.35% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $189.02 | -96.30% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $12.37 | -2.99% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.38 | +986.96% | 1 | Oct 11, 2022 |
Corcept Therapeutics
Dec 16, 2025
Initiates: Neutral
Price Target: $95
Current: $79.82
Upside: +19.02%
Legend Biotech
Dec 8, 2025
Maintains: Buy
Price Target: $54 → $48
Current: $21.92
Upside: +118.98%
Biohaven
Nov 26, 2025
Downgrades: Neutral
Price Target: $26 → $11
Current: $11.54
Upside: -4.68%
Jazz Pharmaceuticals
Nov 24, 2025
Downgrades: Neutral
Price Target: $163 → $188
Current: $170.50
Upside: +10.26%
Alvotech
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $4.97
Upside: +101.21%
AbbVie
Nov 7, 2025
Maintains: Neutral
Price Target: $195 → $220
Current: $230.84
Upside: -4.70%
United Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $580 → $600
Current: $502.90
Upside: +19.31%
Exelixis
Nov 6, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $45.37
Upside: -11.84%
Avadel Pharmaceuticals
Oct 28, 2025
Downgrades: Neutral
Price Target: $20
Current: $21.55
Upside: -7.19%
Harmony Biosciences Holdings
Oct 15, 2025
Maintains: Buy
Price Target: $50 → $43
Current: $37.91
Upside: +13.43%
Oct 9, 2025
Maintains: Buy
Price Target: $188 → $195
Current: $143.64
Upside: +35.76%
Sep 24, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $31.56
Upside: -17.62%
Sep 9, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $27.26
Upside: +43.07%
Aug 6, 2025
Maintains: Buy
Price Target: $133 → $144
Current: $150.68
Upside: -4.43%
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $25.61
Upside: -29.71%
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $28.01
Upside: +49.95%
Jun 3, 2025
Maintains: Neutral
Price Target: $61
Current: $99.29
Upside: -38.56%
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $61.75
Upside: -33.60%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.34
Upside: -21.64%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $65.16
Upside: +74.95%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $39.08
Upside: -28.35%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $189.02
Upside: -96.30%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $12.37
Upside: -2.99%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $1.38
Upside: +986.96%